Employees: 11 (2023.0)Legal category: 5485Size: PMECreation date: 2010-03-11 (16 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: TEMPLEUVE-EN-PEVELE (59242), Nord
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
PHARMACIE BERTRAND VAN TRIEMPONT : revenue, balance sheet and financial ratios
PHARMACIE BERTRAND VAN TRIEMPONT is a French company
founded 16 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in TEMPLEUVE-EN-PEVELE (59242),
this company of category PME
shows in 2025 a net income positive of 392 k€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMACIE BERTRAND VAN TRIEMPONT (SIREN 520911595)
Indicator
2025
2024
2022
2021
2020
2019
2018
2017
2016
2015
Revenue
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net income
392 284 €
268 125 €
345 173 €
281 173 €
303 214 €
317 514 €
297 759 €
238 877 €
287 847 €
273 084 €
EBITDA
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, PHARMACIE BERTRAND VAN TRIEMPONT generates positive net income of 392 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2015-2025: 273 k€ -> 392 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
392 284 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 10%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 80%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
9.608%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
79.53%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Solvency indicators evolution PHARMACIE BERTRAND VAN TRIEMPONT
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2015
2016
2017
2018
2019
2020
2021
2022
2024
2025
Debt ratio
133.227
95.785
70.107
46.819
28.45
15.666
5.162
16.022
14.165
9.608
Financial autonomy
38.968
46.267
53.563
61.137
69.677
77.232
85.808
76.27
76.475
79.53
Repayment capacity
None
None
None
None
None
None
None
None
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
None%
None%
None%
None%
Sector positioning
Debt ratio
9.612025
2022
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Excellent
In 2025, the debt ratio of PHARMACIE BERTRAND VAN TR... (9.61) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
79.53%2025
2022
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Excellent+5 pts over 3 years
In 2025, the financial autonomy of PHARMACIE BERTRAND VAN TR... (79.5%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 276.42. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
276.421
Liquidity indicators evolution PHARMACIE BERTRAND VAN TRIEMPONT
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2015
2016
2017
2018
2019
2020
2021
2022
2024
2025
Liquidity ratio
259.953
264.255
273.006
244.576
240.287
242.1
253.609
230.374
232.602
276.421
Interest coverage
None
None
None
None
None
None
None
None
None
None
Sector positioning
Liquidity ratio
276.422025
2022
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Excellent+15 pts over 3 years
In 2025, the liquidity ratio of PHARMACIE BERTRAND VAN TR... (276.42) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMACIE BERTRAND VAN TRIEMPONT
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2015
2016
2017
2018
2019
2020
2021
2022
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
0 €
0 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
0
0
0
0
Customer payment term (days)
164
158
0
215
161
162
0
0
0
0
Supplier payment term (days)
891
719
0
873
885
845
731
0
0
0
Positioning of PHARMACIE BERTRAND VAN TRIEMPONT in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of PHARMACIE BERTRAND VAN TRIEMPONT is estimated at
6 231 477 €
(range 4 228 710€ - 9 778 047€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
4228k€6231k€9778k€
6 231 477 €Range: 4 228 710€ - 9 778 047€
NAF 5 année 2025
Valuation method used
Net Income Multiple
392 284 €
×
15.9x
=6 231 478 €
Range: 4 228 710€ - 9 778 047€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMACIE BERTRAND VAN TRIEMPONT with other companies in the same sector:
Frequently asked questions about PHARMACIE BERTRAND VAN TRIEMPONT
What is the revenue of PHARMACIE BERTRAND VAN TRIEMPONT ?
The revenue of PHARMACIE BERTRAND VAN TRIEMPONT is not publicly disclosed (confidential accounts filed with INPI).
Is PHARMACIE BERTRAND VAN TRIEMPONT profitable?
Yes, PHARMACIE BERTRAND VAN TRIEMPONT generated a net profit of 392 k€ in 2025.
Where is the headquarters of PHARMACIE BERTRAND VAN TRIEMPONT ?
The headquarters of PHARMACIE BERTRAND VAN TRIEMPONT is located in TEMPLEUVE-EN-PEVELE (59242), in the department Nord.
Where to find the tax return of PHARMACIE BERTRAND VAN TRIEMPONT ?
The tax return of PHARMACIE BERTRAND VAN TRIEMPONT is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMACIE BERTRAND VAN TRIEMPONT operate?
PHARMACIE BERTRAND VAN TRIEMPONT operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart